Ivan Bergstein
2017
In 2017, Ivan Bergstein earned a total compensation of $3.4M as President and Chief Executive Officer at Stemline Therapeutics, a 1% decrease compared to previous year.
Compensation breakdown
| Bonus | $457,346 |
|---|---|
| Non-Equity Incentive Plan | $52,632 |
| Salary | $554,359 |
| Stock Awards | $2,343,308 |
| Total | $3,407,645 |
Bergstein received $2.3M in stock awards, accounting for 69% of the total pay in 2017.
Bergstein also received $457.3K in bonus, $52.6K in non-equity incentive plan and $554.4K in salary.
Rankings
In 2017, Ivan Bergstein's compensation ranked 3,106th out of 14,666 executives tracked by ExecPay. In other words, Bergstein earned more than 78.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,106 out of 14,666 | 79th |
Division Manufacturing | 1,071 out of 5,772 | 81st |
Major group Chemicals And Allied Products | 291 out of 2,075 | 86th |
Industry group Drugs | 222 out of 1,731 | 87th |
Industry Pharmaceutical Preparations | 176 out of 1,333 | 87th |
Source: SEC filing on April 30, 2018.
Bergstein's colleagues
We found two more compensation records of executives who worked with Ivan Bergstein at Stemline Therapeutics in 2017.